Omeros Corporation
Clinical trials sponsored by Omeros Corporation, explained in plain language.
-
New PNH drug shows promise in early trial
Disease control CompletedThis early-stage study tested a new drug, OMS906, in 15 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The main goal was to check safety and how the body processes the drug, while also looking for early signs that it might help control the disease. …
Phase: PHASE1 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 26, 2026 09:08 UTC
-
New hope for PNH patients failing standard therapy
Disease control CompletedThis study tested a new drug called OMS906 in 12 adults with PNH, a rare blood disease, who were not getting enough benefit from the standard treatment ravulizumab. The goal was to see if OMS906 is safe and can raise hemoglobin levels. Participants received OMS906 every 8 weeks, …
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 22, 2026 13:55 UTC